Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Putting the MD back into MDMA

A phase 3 study shows that MDMA may be a promising treatment for PTSD, which will require a shift in how this drug is perceived.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: The brain pathways of PTSD and site of action of MDMA in therapy.


  1. 1.

    Mitchell, J. M. et al. Nat. Med. (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Freudenmann, R. W., Oxler, F. & Bernschneider-Reif, S. Addiction 101, 1241–1245 (2006).

    Article  Google Scholar 

  3. 3.

    Mithoefer, M. C. et al. J. Psychopharmacol. 25, 439–452 (2011).

    CAS  Article  Google Scholar 

  4. 4.

    Sessa, B. et al. J. Psychopharmacol. 35, 375–383 (2021).

    CAS  Article  Google Scholar 

  5. 5.

    Kuypers, K. P. et al. Psychopharmacology (Berl.) 235, 481–490 (2018).

    CAS  Article  Google Scholar 

  6. 6.

    Nardou, R. et al. Nature 569, 116–120 (2019).

    CAS  Article  Google Scholar 

  7. 7.

    Feduccia, A. A. & Mithoefer, M. C. Prog. Neuropsychopharmacol. Biol. Psychiatry 84, 221–228 (2018).

    CAS  Article  Google Scholar 

  8. 8.

    Carhart-Harris, R. L. et al. Int. J. Neuropsychopharmacol. 1, 527–540 (2013).

    Google Scholar 

  9. 9.

    Bedi, G., Phan, K. L., Angstadt, M. & de Wit, H. Psychopharmacology (Berl.) 207, 73–83 (2009).

    CAS  Article  Google Scholar 

  10. 10.

    Carhart-Harris, R. L. et al. Biol. Psychiatry 78, 554–562 (2014).

    Article  Google Scholar 

  11. 11.

    Hysek, C. M. et al. Soc. Cogn. Affect. Neurosci. 9, 1645–1652 (2014).

    Article  Google Scholar 

  12. 12.

    Wardle, M. C. & de Wit, H. Psychopharmacology (Berl.) 231, 4219–4229 (2014).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to David J. Nutt.

Ethics declarations

Competing interests

D.J.N. is a paid advisor to Awakn, a company with an interest in MDMA treatment research.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nutt, D.J., de Wit, H. Putting the MD back into MDMA. Nat Med 27, 950–951 (2021).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing